Fig. 5: Study design and efficacy of anti-hTfR1 antibody treatment in JUNV-infected hTfR1 mice (Trial 2). | Nature Communications

Fig. 5: Study design and efficacy of anti-hTfR1 antibody treatment in JUNV-infected hTfR1 mice (Trial 2).

From: Host receptor-targeted therapeutic approach to counter pathogenic New World mammarenavirus infections

Fig. 5

a Experimental design, b survival outcomes (n = 6–8 mice/treatment group, n = 16 placebo-treated mice, n = 3 untreated sham-infected controls), c percent change in body weight represented as a group mean ± standard error of the surviving animals compared to their starting weights on the day of infection, and d clinical disease scores represented as group mean ± standard error during the course of the experiment. aLog-rank Mantel-Cox test. Antibody (Ab); Undefined, >50% survival. Source data are included in the Source Data file.

Back to article page